October 18th 2024
The FREEDOM2 study demonstrates that fedratinib is an effective second-line treatment for myelofibrosis after ruxolitinib failure or intolerance.
September 30th 2024
September 13th 2024
September 12th 2024
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Ruxolitinib Extended-Release Could Mitigate Risk/Increase Compliance for Patients With MPNs
March 24th 2023In an interview with Targeted Oncology, Aaron T. Gerds, MD, MS, provided an in-depth discussion on the complete response letter issued to ruxolitinib extended-release, and why continued evaluation of the agent could be beneficial for patients with MPNs.
Read More
FDA Issues Complete Response Letter to Ruxolitinib XR Tablets for MPNs
March 24th 2023The FDA noted that additional requirements are needed prior to the approval of ruxolitinib extended-release for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease, in a complete response letter.
Read More
Abbas Assesses the Use of Allogenic Transplant In MPNs
March 23rd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Jonathan Abbas, MD, discussed with his fellow clinicians the use of allogeneic hematopoietic stem cell transplant in patients with myeloproliferative neoplasms and how ruxolitinib fits into their care.
Read More
Accelerated Dosing of Ropeginterferon Alfa-2b May Improve Responses in PV
February 6th 2023The dose and titration of ropeginterferon alfa-2b is safe and effective for patients with polycythemia vera. However, additional studies are needed to provide rationale for an amended, higher initial dosage, and rapid titration.
Read More
Roundtable Discussion: Komrokji Evaluates Pathology, Risk Assessment, and Therapy for Myelofibrosis
January 14th 2023During a Targeted Oncology case-based roundtable event, Rami Komrokji, MD, discussed with participants their approach toward assessing and treating a patient with symptoms possibly indicating primary myelofibrosis.
Read More
Ruxolitinib’s Role for Symptoms and Survival Benefit in Myelofibrosis
January 4th 2023During a Targeted Oncology case-based roundtable event, Rami Komrokji, MD, discussed data supporting the use of ruxolitinib and what role it may play in improving long-term outcomes for patients with myelofibrosis. This is the second of 2 articles based on this event.
Read More
Roundtable Discussion: Pettit Reviews Use of JAK Inhibitors for High-risk Myelofibrosis
November 28th 2022During a Targeted Oncology case-based roundtable event, Kristen M. Pettit, MD, discussed with participants the case of a patient with high-risk primary myelofibrosis and significant cytopenias.
Read More